ALSO NOTED: Forest sues generics over Namenda; Omrix gets new indication for Evicel;

> Forest Labs and Merck KGaA are suing several generics makers--including Barr, Cobalt, Lupin, Orchid, Teva, and Wockhardt--for infringing patents on the Namenda treatment for Alzheimer's. Report

> Omrix Biopharmaceuticals got the FDA's blessing for a new use of its Evicel sealant product. Report

> FDA approvals may be down in the doldrums, but approvable letters flew out of the agency in 2007--at a rate 40 percent higher than in 2006. Report

> The FDA is postponing its review of an anti-constipation drug candidate developed by Progenics and Wyeth. Report

> UK investors are turning up their noses at biotech these days, but a few companies are poised for a comeback. Report

> Is Pfizer a good buy now that shares are going for just 10 times forecast earnings? Smart Money does the analysis. Report

> UK pharmacies are launching an online registration system to help curb online sales of fake and dangerous medicines. Report

> Noven Pharmaceuticals got an FDA warning of potential manufacturing deficiencies at its Miami plant; the problems related to Noven's Daytrana transdermal product. Report

And Finally... Next time you fight with your spouse over getting directions, you'll know to blame your brain. Report